A super-enhancer-related gene signature predicts prognosis and immune microenvironment features in glioma.

IF 1.5 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cellular and molecular biology Pub Date : 2025-07-06 DOI:10.14715/cmb/2025.71.6.14

Huijun Li, Bin Luo, Yibadaiti Tulufu, Xiong Wang, Daoyuan Yue

{"title":"A super-enhancer-related gene signature predicts prognosis and immune microenvironment features in glioma.","authors":"Huijun Li, Bin Luo, Yibadaiti Tulufu, Xiong Wang, Daoyuan Yue","doi":"10.14715/cmb/2025.71.6.14","DOIUrl":null,"url":null,"abstract":"<p><p>Glioma is the most frequent malignant tumor in the brain. Super-enhancer (SE) is a class of transcriptional activator, which drives gene expression. SE-related genes (SERGs) affect occurrence and development of several tumors. We explored the predictive role of SERGs in the prognosis and immune features of glioma. A total of 1557 glioma patients were collected from four data sets, including The Cancer Genomic Atlas (TCGA, n = 691), the Chinese Glioma Genomic Atlas (CGGA) array (n = 286), the CGGA sequencing (n = 316), and GSE16011 (n = 264) from Gene Expression Omnibus (GEO) database. SERGs were selected from SEdb (http://www.licpathway.net/sedb), a comprehensive human SE database. Survival analysis and visualization were performed using the R packages survival (v3.3-1) and survminer (v0.4.9). Immune subtype classification was conducted with the ImmuneSubtypeClassifier (v0.1.0) R package. A nomogram was generated using the rms (v6.7-1) package. A risk score model based on 13 super-enhancer-related genes (SERGs) was constructed, demonstrating that patients in the low-risk group had significantly better prognosis. The SERGs signature significantly correlated with age, molecular and immune subtypes, IDH mutation, MTMG promoter methylation, 1p19q co-deletion, and expression of immune checkpoint genes in glioma patients. The SERGs signature could predict the prognosis and immune features of glioma, and SERGs might serve as novel immunotherapy options for glioma.</p>","PeriodicalId":9802,"journal":{"name":"Cellular and molecular biology","volume":"71 6","pages":"102-109"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular and molecular biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.14715/cmb/2025.71.6.14","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Glioma is the most frequent malignant tumor in the brain. Super-enhancer (SE) is a class of transcriptional activator, which drives gene expression. SE-related genes (SERGs) affect occurrence and development of several tumors. We explored the predictive role of SERGs in the prognosis and immune features of glioma. A total of 1557 glioma patients were collected from four data sets, including The Cancer Genomic Atlas (TCGA, n = 691), the Chinese Glioma Genomic Atlas (CGGA) array (n = 286), the CGGA sequencing (n = 316), and GSE16011 (n = 264) from Gene Expression Omnibus (GEO) database. SERGs were selected from SEdb (http://www.licpathway.net/sedb), a comprehensive human SE database. Survival analysis and visualization were performed using the R packages survival (v3.3-1) and survminer (v0.4.9). Immune subtype classification was conducted with the ImmuneSubtypeClassifier (v0.1.0) R package. A nomogram was generated using the rms (v6.7-1) package. A risk score model based on 13 super-enhancer-related genes (SERGs) was constructed, demonstrating that patients in the low-risk group had significantly better prognosis. The SERGs signature significantly correlated with age, molecular and immune subtypes, IDH mutation, MTMG promoter methylation, 1p19q co-deletion, and expression of immune checkpoint genes in glioma patients. The SERGs signature could predict the prognosis and immune features of glioma, and SERGs might serve as novel immunotherapy options for glioma.

查看原文本刊更多论文

超增强子相关基因标记预测胶质瘤的预后和免疫微环境特征。

神经胶质瘤是脑部最常见的恶性肿瘤。超级增强子（Super-enhancer， SE）是一类驱动基因表达的转录激活子。se相关基因（serg）影响多种肿瘤的发生和发展。我们探讨了SERGs在胶质瘤的预后和免疫特征中的预测作用。共收集胶质瘤患者1557例，数据来自4个数据集，包括癌症基因组图谱（TCGA, n = 691）、中国胶质瘤基因组图谱（CGGA）阵列（n = 286）、CGGA测序（n = 316）和基因表达Omnibus （GEO）数据库的GSE16011 （n = 264）。serg选自SEdb (http://www.licpathway.net/sedb)，一个综合性的人类SE数据库。使用R软件包Survival （v3.3-1）和survminer （v0.4.9）进行生存分析和可视化。使用ImmuneSubtypeClassifier (v0.1.0) R包进行免疫亚型分类。使用rms （v6.7-1）包生成了一个图。构建了基于13个超增强相关基因（serg）的风险评分模型，结果显示低危组患者预后明显较好。在胶质瘤患者中，SERGs特征与年龄、分子和免疫亚型、IDH突变、MTMG启动子甲基化、1p19q共缺失和免疫检查点基因表达显著相关。serg标记可以预测胶质瘤的预后和免疫特征，serg可能成为胶质瘤新的免疫治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular and molecular biology 生物-生化与分子生物学

CiteScore

1.60

自引率

12.50%

发文量

331

期刊介绍： Cellular and Molecular Biology publishes original articles, reviews, short communications, methods, meta-analysis notes, letters to editor and comments in the interdisciplinary science of Cellular and Molecular Biology linking and integrating molecular biology, biophysics, biochemistry, enzymology, physiology and biotechnology in a dynamic cell and tissue biology environment, applied to human, animals, plants tissues as well to microbial and viral cells. The journal Cellular and Molecular Biology is therefore open to intense interdisciplinary exchanges in medical, dental, veterinary, pharmacological, botanical and biological researches for the demonstration of these multiple links.